• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Zimmer Biomet beats The Street in Q4, expects continued ‘macro pressures’

Zimmer Biomet beats The Street in Q4, expects continued ‘macro pressures’

February 3, 2023 By Sean Whooley

Zimmer Biomet logoZimmer Biomet (NYSE:ZBH) stock is up today on fourth-quarter results that beat the consensus forecast.

Shares of ZBH rose more than 1% at $129.75 apiece by afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up more than 14%.

The Warsaw, Indiana–based orthopedic device maker posted losses of $130.5 million. That amounts to 62¢ per share on sales of $1.83 billion for the three months ended Dec. 31, 2022.

Zimmer Biomet’s losses continued to slide, dipping from $84 million this time last year. However, the company recorded sales growth of 2.7%.

Adjusted to exclude one-time items, earnings per share totaled $1.88. That comes in 5¢ ahead of expectations on Wall Street. Zimmer Biomet also beat The Street on sales, as analysts projected revenues of $1.76 billion.

Highlights in the quarter included the FDA clearance of the Persona OsseoTi keel tibia for cementless knee replacement. Just after the quarter ended, the company also announced plans to acquire soft tissue healing company Embody.

Zimmer Biomet is looking to achieve attractive growth

“We closed out the fourth quarter strong, driven by the solid execution of our team and meaningful innovation in our portfolio – all against a backdrop of continued recovery post-pandemic,” said Bryan Hanson, chair, president and CEO of Zimmer Biomet. “As we enter 2023, we expect macro pressures to continue, but also to stabilize, setting up ZB to achieve attractive growth and mark another key milestone in our transformation journey. We remain committed to building out our portfolio, delivering on our mission and creating value for all of our stakeholders.”

Zimmer Biomet expects 2023 revenues to grow between 1.5% and 3.5%. (Meanwhile, one of its top competitors — Stryker — says it’s entering 2023 with good momentum.) ZB forecasts adjusted EPS to range between $6.95 and $7.15.

BTIG analysts kept their Neutral rating on ZBH shares. But they also noted that Zimmer Biomet executed well through 2022, with growing enthusiasm for the company.

Filed Under: Business/Financial News, Featured, Implants, MassDevice Earnings Roundup, News Well, Orthopedics, Wall Street Beat Tagged With: Zimmer Biomet

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy